Askari M, Faryabi R, Mozaffari H, Darooghegi Mofrad M
MGF Research# MGF research originates primarily from the laboratory of Geoffrey Goldspink at University College London: Discovery and characterization : First described in the late 1990s as a mechanically sensitive IGF-1 splice variant in rabbit and human skeletal muscle Satellite cell activation : Demonstrated ability to activate quiescent satellite cells in culture, with evidence for IGF-1R-independent signaling Cardiac applications : Expression of IGF-1Ec documented in cardiac muscle following myocardial infarction, with preclinical evidence for cardioprotective effects Neuroprotection : MGF expression detected in brain tissue following ischemic injury, with preliminary evidence for neuronal survival effects Aging research : Impaired MGF upregulation documented in elderly subjects after exercise, suggesting a mechanism for age-related decline in regenerative capacity MGF remains entirely preclinical, with no human clinical trials

FDA-approved labels, explain that tirzepatide may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying
Downregulation of CAV1 reduces the levels of GPX4 and FTH1, increases ROS and Fe 2+ concentrations, promotes ferroptosis, and reduces cancer cell migration and invasion, 171 suggesting that the regulatory pathways of CAV1 and ferroptosis may be potential targets for diagnosis and combination therapy strategies in patients with HNSCC